Daewoong Pharmaceutical Secures U.S. Patent Decision for mRNA Delivery Technology, Advancing Anti-Aging Drug Strategy

Daewoong Pharmaceutical has secured a U.S. patent decision for its mRNA delivery technology, marking progress in its anti-aging drug strategy. The patent, covering ionizable lipid structures and related lipid nanoparticle (LNP) compositions, addresses the critical challenge of delivering mRNA molecules to target cells, as these molecules are inherently unstable and cannot enter cells independently.

Daewoong's acquisition of intellectual property and assets related to cellular reprogramming from U.S.-based Turn Biotechnologies further supports its strategy, which aims to control both the mRNA therapeutic and the delivery system required to administer it. This patent decision is significant as it provides intellectual property protection for an enabling technology rather than a single drug candidate, becoming increasingly important in the competitive mRNA landscape.

Brief written by urgent.news from Korea IT Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.